Front. Microbiol. Frontiers in Microbiology Front. Microbiol. 1664-302X Frontiers Media S.A. 10.3389/fmicb.2023.1343080 Microbiology Correction Corrigendum: Hantavirus: an overview and advancements in therapeutic approaches for infection Afzal Samia 1 Ali Liaqat 2 * Batool Anum 2 Afzal Momina 1 Kanwal Nida 2 Hassan Muhammad 1 Safdar Muhammad 1 Ahmad Atif 1 Yang Jing 3 * 1CEMB, University of the Punjab, Lahore, Pakistan 2Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi, Pakistan 3Wuhan Institute of Biological Products Co., Ltd., Wuhan, Hubei, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Liaqat Ali liaqatbiotech@gmail.com Jing Yang WIBPJYang@126.com 12 12 2023 2023 14 1343080 22 11 2023 23 11 2023 Copyright © 2023 Afzal, Ali, Batool, Afzal, Kanwal, Hassan, Safdar, Ahmad and Yang. 2023 Afzal, Ali, Batool, Afzal, Kanwal, Hassan, Safdar, Ahmad and Yang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Hantavirus: an overview and advancements in therapeutic approaches for infection by Afzal, S., Ali, L., Batool, A., Afzal, M., Kanwal, N., Hassan, M., Safdar, M., Ahmad, A., and Yang, J. (2023). Front. Microbiol. 14:1233433. doi: 10.3389/fmicb.2023.1233433 hantavirus HFRS HPS immunotherapy siRNA section-at-acceptance Virology

In the published article, there were errors in Table 1, Table 3, and Table 4.

The caption for Table 1 only listed North and South America, but Table 1 contains countries from North, Central, and South America.

In Table 1, the reference for the row “Canada” was incorrectly listed as “Jonsson et al. (2010)”. The correct reference is “Warner et al. (2020)”.

In Table 1, the reference for the row “Panama” was incorrectly listed as “Martinez-Valdebenito et al. (2014)”. The correct reference is “Armién et al. (2023)”. The corrected Table 1 and its caption “Reported HTNV cases across North, Central, and South America.” appear below.

Reported HTNV cases across North, Central, and South America.

Country Cases Year Source
USA 850 1993–2021 CDC
Canada 143 As of 2020 Warner et al. (2020)
Panama 712 1999–2019 Armién et al. (2023)
Costa Rica 3 Till 2016 PAHO
Argentina 1,350 As 2016 PAHO
Chile 1,028 As of 2016 PAHO
Brazil 2,032 Till 2017 PAHO
Paraguay 319 Till 2016 PAHO
Uruguay 169 Till 2016 PAHO
Bolivia 300 Till 2016 PAHO
Ecuador 73 As of 2016 PAHO
Peru 6 As of 2016 PAHO
French Guiana 3 Till 2016 PAHO

In Table 3, the reference for the row “Lactoferrin” was incorrectly listed as “Gorbunova et al. (2010) and Arikawa et al. (1989)”. The correct reference is “Murphy et al. (2000, 2001)”.

In Table 3, the reference for the row “Ribavirin” was incorrectly listed as “Schmaljohn et al. (1990) and Liang et al. (1996)”. The correct reference is “Chung et al. (2013) and Ogg et al. (2013)”.

In Table 3, the reference for the row “Favipiravir” was incorrectly listed as “Arikawa et al. (1992)”. The correct reference is “Safronetz et al. (2013)”.

In Table 3, the reference for the row “Vandenatib” was incorrectly listed as “Garrido et al. (2018)”. The correct reference is “Bird et al. (2016)”.

In Table 3, the reference for the row “ETAR” was incorrectly listed as “Golias et al. (2007)”. The correct reference is “Chung et al. (2008)”.

In Table 3, the reference for the row “Coritcosteroids” was incorrectly listed as “Mills et al. (1999) and Xu et al. (2009)”. The correct reference is “Vial et al. (2013) and Brocato and Hooper (2019)”.

In Table 3, the reference for the row “Human Immune Sera” was incorrectly listed as “Tian et al. (2021)”. The correct reference is “Vial et al. (2015)”.

In Table 3, the reference for the row “JL16 and MIB22” was incorrectly listed as “Weinberg and Arbuthnot (2010)”. The correct reference is “Garrido et al. (2018)”.

In Table 3, the reference for the row “Domain III and Stem Peptides” was incorrectly listed as “Taylor et al. (2013)”. The correct reference is “Barriga et al. (2016)”.

In Table 3, the reference for the row “CLVRNLAWC and CQATTARNC” was incorrectly listed as “Cicardi et al. (2010)”. The correct reference is “Hall et al. (2008)”.

In Table 3, the reference for the row “Incatibant” was incorrectly listed as “Avižiniene et al. (2023) and Mittler et al. (2023)”. The correct reference is “Antonen et al. (2013) and Laine et al. (2015)”.

In Table 3, the reference for the row “TNF-α” was incorrectly listed as “Brocato et al. (2012), Manigold and Vial (2014), and Vial et al. (2015)”. The correct reference is “Vilcek (1991), Sundstrom et al. (2001), and Maes et al. (2004)”.

In Table 3, the reference for the row “RANTES/IP-10/MCP-1” was incorrectly listed as “Manigold and Vial (2014), and Malley et al. (2004)”. The correct reference is “Sundstrom et al. (2001) and Glass et al. (2003)”. The corrected Table 3 and its caption “Lists some examples of potential antiviral therapies against Hantavirus.” appear below.

Lists some examples of potential antiviral therapies against Hantavirus.

Antiviral therapy Type Function Target Disease References
Lactoferrin Lactoferrin Block viral entry Viral GP HFRS Murphy et al. (2000, 2001)
Ribavirin Nucleoside analogs Inhibit viral replication RdRp HCPS and HFRS Chung et al. (2013) and Ogg et al. (2013)
Favipiravir Pyrazine derivatives Block viral entry RdRp HCPS Safronetz et al. (2013)
Vandetanib Tyrosine kinase inhibitor Improve vascular function VEGF/Vascular function HCPS Bird et al. (2016)
ETAR Nucleoside analog Inhibit viral entry RdRp HCPS and HFRS Chung et al. (2008)
Corticosteroids Hormone Rebuild immune homeostasis Immunotherapy HCPS and HFRS Vial et al. (2013) and Brocato and Hooper (2019)
Human Immune Sera Human pAbs Block viral entry Viral GP HCPS Vial et al. (2015)
JL16 and MIB22 Human mAbs Block viral entry Viral GP HCPS Garrido et al. (2018)
Domain III and stem peptides Peptides Block viral entry Gc glycoprotein HCPS and HFRS Barriga et al. (2016)
CLVRNLAWC and CQATTARNC Cyclic nonapeptides Block viral entry Host receptor HCPS Hall et al. (2008)
Icatibant Small molecule Improve vascular function BK type 2 receptor HFRS Antonen et al. (2013) and Laine et al. (2015)
TNF-α Small proteins/Pro- inflammatory cytokines Increase systemic toxicity Vascular function HCPS and HFRS Vilcek (1991), Sundstrom et al. (2001) and Maes et al. (2004)
RANTES/IP- 10/MCP-1 Small proteins/ Pro-inflammatory chemokines Immunomodulators/ Inhibit viral infection Microvascular endothelium HFRS Sundstrom et al. (2001) and Glass et al. (2003)

In Table 4, the reference for the row “Inactivated Vaccine” was incorrectly listed as “Sroga et al. (2021)”. The correct reference is “Khan et al. (2019)”.

In Table 4, the reference for the row “Virus-like Particles 1” was incorrectly listed as “Jonsson et al. (2005)”. The correct reference is “Dong et al. (2019)”.

In Table 4, the reference for the row “Virus-like Particles 2” was incorrectly listed as “Wray et al. (1985)”. The correct reference is “Dong et al. (2019)”.

In Table 4, the reference for the row “Virus-Vector Vaccines 1” was incorrectly listed as “Hopper et al. (1999)”. The correct reference is “Warner et al. (2019)”.

In Table 4, the reference for the row “Virus-Vector Vaccines 2” was incorrectly listed as “Brocato et al. (2013)”. The correct reference is “Prescott et al. (2014)”.

In Table 4, the reference for the row “Virus-Vector Vaccines 3” was incorrectly listed as “Deng et al. (2020)”. The correct reference is “Safronetz et al. (2009)”.

In Table 4, the reference for the row “Recombinant Vaccines 1” was incorrectly listed as “Hopper et al. (2014)”. The correct reference is “Geldmacher et al. (2004)”.

In Table 4, the reference for the row “Recombinant Vaccines 2” was incorrectly listed as “Ogg et al. (2013)”. The correct reference is “de Carvalho et al. (2002)”.

In Table 4, the reference for the row “Recombinant Vaccines 3” was incorrectly listed as “Ogg et al. (2013)”. The correct reference is “Maes et al. (2006)”.

In Table 4, the reference for the row “DNA Vaccines 1” was incorrectly listed as “Vial et al. (2013)”. The correct reference is “Hooper et al. (2013)”.

In Table 4, the reference for the row “DNA Vaccines 2” was incorrectly listed as “Antonen et al. (2013)”. The correct reference is “Hooper et al. (2001)”.

In Table 4, the reference for the row “DNA Vaccines 3” was incorrectly listed as “Laine et al. (2015)”. The correct reference is “Hooper et al. (2006)”.

In Table 4, the reference for the row “DNA Vaccines 4” was incorrectly listed as “Vial et al. (2013)”. The correct reference is “Hooper et al. (2013)”.

In Table 4, the reference for the row “DNA Vaccines 5” was incorrectly listed as “Fire et al. (1998)”. The correct reference is “Brocato et al. (2013)”.

In Table 4, the reference for the row “DNA Vaccines 6” was incorrectly listed as “Safronetz et al. (2013)”. The correct reference is “Jiang et al. (2017)”.

In Table 4, the reference for the row “Subunit Vaccines” was incorrectly listed as “Ye et al. (2019)”. The correct reference is “Maes et al. (2008)”. The corrected Table 4 and its caption “Describing evaluation of Hantavirus vaccines in various animal models and some vaccines currently undergoing clinical trials.” appear below.

Describing evaluation of Hantavirus vaccines in various animal models and some vaccines currently undergoing clinical trials.

Vaccine type Antigen Animal model Immunogenicity evaluation References
Inactivated vaccine Formalin inactivated HNTV Humans Humoral response Neutralizing antibodies Khan et al. (2019)
Virus-like particles HTNV-VLP with CD40L or GM-CSF Mice Cytotoxic response Neutralization antibody Cytolytic activity Dong et al. (2019)
M DHFR-deficient CHO cells Antigen-specific IFN-γ production Effective against HTNV Still in developing phases Dong et al. (2019)
Virus-vector vaccines Replication-competent VSV-vectored SNV or ANDV glycoproteins Syrian Hamster Cross-reactive IgG antibodies Neutralizing antibodies Warner et al. (2019)
Replication-competent VSV-vectored ANDV glycoproteins Syrian Hamsters Neutralizing antibodies Prescott et al. (2014)
Non-replicating Ad vector expressing N, Gn, Gc, or Gn/Gc Syrian Hamsters CD8+ cell response Neutralizing antibodies Safronetz et al. (2009)
Recombinant vaccines Yeast-expressed DOBV nucleoprotein Mice NP-specific IgG response Th1/Th2 response Cross-reactivity with HTNV and PUUV Geldmacher et al. (2004)
Nucleoproteins from ANDV, TOPV, DOBV or PUUV Bank voles Specific CD8+ cell production Cross-reactive response against PUUV de Carvalho et al. (2002)
Truncated recombinant PUUV nucleoprotein linked to bacterial membrane protein Mice CD8+ T-cell response NP IgG response Maes et al. (2006)
DNA vaccines HTNV/PUUV/SNV/ANDV M gene segment mix Rabbits Neutralizing antibodies Hooper et al. (2013)
HTNV M segment Rhesus macaques Neutralizing antibodies Cross-reactivity with SEOV and DOBV Hooper et al. (2001)
ANDV and HNTV M gene segments Rhesus macaques Neutralizing antibodies Hooper et al. (2006)
SNV M gene segment Syrian hamsters Neutralizing antibodies Hooper et al. (2013)
PUUV M gene segment Syrian hamsters Protection against lethal ANDV infection, without nAbs Neutralizing antibodies Brocato et al. (2013)
Gn glycoprotein BALB/c mice Effective against HTNV Still in developing phases Jiang et al. (2017)
Subunit vaccines NP (nucleocapsid protein) E. coli mutant ICONE NMRI mice Effective against PUUV In developing Phases Maes et al. (2008)

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Antonen J. Leppänen I. Tenhunen J. Arvola P. Mäkelä S. Vaheri A. . (2013). A severe case of Puumala Hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Scand. J. Infect. Dis. 45, 494–496. 10.3109/00365548.2012.75526823294035 Armién B. Muñoz C. Cedeño H. Salazar J. R. Salinas T. P. González P. . (2023). Hantavirus in Panama: twenty years of epidemiological surveillance experience. Viruses 15:1395. 10.3390/v1506139537376694 Barriga G. P. Villalón-Letelier F. Márquez C. L. Bignon E. A. Acuña R. Ross B. H. . (2016). Inhibition of the Hantavirus fusion process by predicted domain III and stem peptides from glycoprotein Gc. PLoS Negl. Trop. Dis. 10:e0004799. 10.1371/journal.pntd.000479927414047 Bird B. H. Shrivastava-Ranjan P. Dodd K. A. Erickson B. R. Spiropoulou C. F. (2016). Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome. Antivir. Res. 132, 66–69. 10.1016/j.antiviral.2016.05.01427233645 Brocato R. Josleyn M. Wahl-Jensen V. Schmaljohn C. Hooper J. (2013). Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine. Clin. Vaccine Immunol. 20, 218–226. 10.1128/CVI.00546-1223239797 Brocato R. L. Hooper J. W. (2019). Progress on the prevention and treatment of Hantavirus disease. Viruses 11:610. 10.3390/v1107061031277410 Chung D.-H. Kumarapperuma S. C. Sun Y. Li Q. Chu Y.-K. Arterburn J. B. . (2008). Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1, 2, 4] triazole and its in vitro and in vivo efficacy against Hantavirus. Antivir. Res. 79, 19–27. 10.1016/j.antiviral.2008.02.00318394724 Chung D.-H. Västermark Å. Camp J. V. McAllister R. Remold S. K. Chu Y.-K. . (2013). The murine model for Hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment. J. Virol. 87, 10997–11007. 10.1128/JVI.01394-1323903835 de Carvalho N. Gonzalez Delia Valle M. Padula P. Bjorling E. Plyusnin A. Lundkvist A. (2002). Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. J. Virol. 76, 6669–6677. 10.1128/jvi.76.13.6669-6677.200212050380 Dong Y. Ma T. Zhang X. Ying Q. Han M. Zhang M. . (2019). Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection. J. Med. Microbiol. 68, 480–492. 10.1099/jmm.0.00089730657443 Garrido J. L. Prescott J. Calvo M. Bravo F. Alvarez R. Salas A. . (2018). Two recombinant human monoclonal antibodies that protect against lethal Andes Hantavirus infection in vivo. Sci. Transl. Med. 10:eaat6420. 10.1126/scitranslmed.aat642030463919 Geldmacher A. Skrastina D. Petrovskis I. Borisova G. Berriman J. A. Roseman A. M. . (2004). An amino-terminal segment of Hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. Virology 323, 108–119. 10.1016/j.virol.2004.02.02215165823 Glass W. G. Rosenberg H. F. Murphy P. M. (2003). Chemokine regulation of inflammation during acute viral infection. Curr. Opin. Allergy Clin. Immunol. 3, 467–473. 10.1097/00130832-200312000-0000814612671 Hall P. R. Hjelle B. Brown D. C. Ye C. Bondu-Hawkins V. Kilpatrick K. A. . (2008). Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade. Antimicrob. Agents Chemother. 52, 2079–2088. 10.1128/AAC.01415-0718391034 Hooper J. Custer D. Thompson E. Schmaljohn C. (2001). DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J. Virol. 75, 8469–8477. 10.1128/JVI.75.18.8469-8477.200111507192 Hooper J. W. Custer D. M. Smith J. Wahl-Jensen V. (2006). Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347, 208–216. 10.1016/j.virol.2005.11.03516378630 Hooper J. W. Josleyn M. Ballantyne J. Brocato R. (2013). A novel sin Nombre virus DNA vaccine and its inclusion in a candidate pan-Hantavirus vaccine against Hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Vaccine 31, 4314–4321. 10.1016/j.vaccine.2013.07.02523892100 Jiang D.-B. Sun L.-J. Cheng L.-F. Zhang J.-P. Xiao S.-B. Sun Y.-J. . (2017). Recombinant DNA vaccine of Hantavirus Gn and LAMP1 induced long-term immune protection in mice. Antivir. Res. 138, 32–39. 10.1016/j.antiviral.2016.12.00127923570 Khan A. Shin O. S. Na J. Kim J. K. Seong R.-K. Park M.-S. . (2019). A systems vaccinology approach reveals the mechanisms of immunogenic responses to hantavax vaccination in humans. Sci. Rep. 9:4760. 10.1038/s41598-019-41205-130886186 Laine O. Leppänen I. Koskela S. Antonen J. Mäkelä S. Sinisalo M. . (2015). Severe Puumala virus infection in a patient with a lymphoproliferative disease treated with icatibant. Infect. Dis. 47, 107–111. 10.3109/00365548.2014.96930425496418 Maes P. Clement J. Cauwe B. Bonnet V. Keyaerts E. Robert A. . (2008). Truncated recombinant puumala virus nucleocapsid proteins protect mice against challenge in vivo. Viral Immunol. 21, 49–60. 10.1089/vim.2007.005918355122 Maes P. Clement J. Gavrilovskaya I. Van Ranst M. (2004). Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 17, 481–497. 10.1089/vim.2004.17.48115671746 Maes P. Keyaerts E. Bonnet V. Clement J. Avsic-Zupanc T. Robert A. . (2006). Truncated recombinant Dobrava Hantavirus nucleocapsid proteins induce strong, long-lasting immune responses in mice. Intervirology 49, 253–260. 10.1159/00009345416714853 Murphy M. Kariwa H. Mizutani T. Yoshimatsu K. Arikawa J. Takashima I. (2000). In vitro antiviral activity of lactoferrin and ribavirin upon Hantavirus. Arch. Virol. 145, 1571–1582. 10.1007/s00705007007711003470 Murphy M. E. Kariwa H. Mizutani T. Tanabe H. Yoshimatsu K. Arikawa J. . (2001). Characterization of in vitro and in vivo antiviral activity of lactoferrin and ribavirin upon Hantavirus. J. Vet. Med. Sci. 63, 637–645. 10.1292/jvms.63.637 Ogg M. Jonsson C. B. Camp J. V. Hooper J. W. (2013). Ribavirin protects Syrian hamsters against lethal Hantavirus pulmonary syndrome—after intranasal exposure to Andes virus. Viruses 5, 2704–2720. 10.3390/v511270424217424 Prescott J. DeBuysscher B. L. Brown K. S. Feldmann H. (2014). Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters. Viruses 6, 516–523. 10.3390/v602051624492621 Safronetz D. Falzarano D. Scott D. P. Furuta Y. Feldmann H. Gowen B. B. (2013). Antiviral efficacy of favipiravir against two prominent etiological agents of Hantavirus pulmonary syndrome. Antimicrob. Agents Chemother. 57, 4673–4680. 10.1128/AAC.00886-1323856782 Safronetz D. Hegde N. R. Ebihara H. Denton M. Kobinger G. P. St. Jeor S. . (2009). Adenovirus vectors expressing Hantavirus proteins protect hamsters against lethal challenge with Andes virus. J. Virol. 83, 7285–7295. 10.1128/JVI.00373-0919403663 Sundstrom J. B. McMullan L. K. Spiropoulou C. F. Hooper W. C. Ansari A. A. Peters C. J. . (2001). Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. J. Virol. 75, 6070–6085. 10.1128/JVI.75.13.6070-6085.200111390609 Vial P. Valdivieso F. Ferres M. Riquelme R. Rioseco M. Calvo M. . (2013). Hantavirus study Group in Chile High-dose intravenous methylprednisolone for Hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial. Clin. Infect. Dis. 57, 943–951. 10.1093/cid/cit39423784924 Vial P. A. Valdivieso F. Calvo M. Rioseco M. L. Riquelme R. Araneda A. . (2015). A non-randomized multicentre trial of human immune plasma for treatment of Hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir. Ther. 20, 377–386. 10.3851/IMP287525316807 Vilcek J. (1991). Tumor necrosis factor-new insights into the molecular mechanisms of its multiple actions. J. Biol. Chem. 266:7313. 10.1016/S0021-9258(20)89445-91850405 Warner B. M. Dowhanik S. Audet J. Grolla A. Dick D. Strong J. E. . (2020). Hantavirus cardiopulmonary syndrome in Canada. Emerg. Infect. Dis. 26:3020. 10.3201/eid2612.20280833219792 Warner B. M. Stein D. R. Jangra R. K. Slough M. M. Sroga P. Sloan A. . (2019). Vesicular stomatitis virus-based vaccines provide cross-protection against Andes and sin nombre viruses. Viruses 11:645. 10.3390/v1107064531337019